ClinicalTrials.gg
RecruitingNCT06276465PEACE8Updated Dec 20, 2024

Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging

A Phase 3 interventional study of Darolutamide 300 mg and Stereotactic body radiation therapy in Prostatic Cancer, Castration-Resistant, sponsored by UNICANCER. Recruiting at 4 sites in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by UNICANCER · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Prostatic Neoplasms, Castration-Resistant with a site in France — 10 open to participants now, 13 under way, 4 of them phase 3. Prostatic Neoplasms, Castration-Resistant · France.

Planned enrollment
6th of 19
336 · median 180
Started
2024
with 3 others
Phase 3
5 of 19
3 open now
Primary completion
2029-10
later than 10 of 12 live
Registered
11th of 19
by date

Among the 19 studies in Prostatic Neoplasms, Castration-Resistant with a site in France, this one is the 6th largest by planned enrollment, is one of 4 that started in 2024, is one of 5 in phase 3, reaches primary completion later than 10 of the 12 other live ones, and was the 11th registered.

Prostatic Neoplasms, Castration-Resistant

86 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 29 are open to participants now.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Open to participants now

10 of the 19 studies in Prostatic Neoplasms, Castration-Resistant with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 26 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (85%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Prostatic Neoplasms, Castration-Resistant with a site in France, or all of them as a file.
02

Study summary

In earlier stages of prostate cancer, male sexual hormones (androgens) stimulate the growth of cancer cells. Castration-resistant prostate cancer (CRPC) means that the prostate cancer continued to grow despite patients are taking hormone therapy to control the disease. One of the standard treatments for these patients is so-called 'new generation' hormonal therapy. These hormone therapies include apalutamide, enzalutamide, or darolutamide. They work by blocking androgen receptors that play an important role in the growth of prostate cancer.

In the case of oligometastatic CRPC, the cancer has gone beyond the prostate and has spread to other organs in the body (metastases), but these metastases remain limited in number.

An early detection of the oligometastatic CRPC and appropriate treatment may prolong survival in these patients.

The treatment proposed as part of this research is a combination of oral darolutamide, approved in Europe to treat patients with CRPC who do not have metastasis visible on CT-scan or bone scintigraphy (but visible with positron emission tomography-scan (PET-Scan), a more precise imaging technique) with stereotactic body radiotherapy (SBRT), a new radiotherapy technique guided by very high precision medical imaging. This method makes it possible to better target cancer cells while preserving neighboring healthy organs.

The principal objective of this trial is to evaluate the efficacy of the combination of SBRT with darolutamide, compared to darolutamide.

Read the detailed description

PEACE 8 is a phase III open-label, randomised (patients are randomly assigned to treatment), international, multicentre trial, evaluating the benefit of adding SBRT to darolutamide for treating patients with oligometastatic CRPC.

Eligible patients will be randomised into either an experimental group receiving darolutamide + SBRT or a control group receiving darolutamide. In both arms, all patients will receive continuous castration (ADT) during the trial course.

Patients' participation in the trial will not exceed 60 months after randomisation, including a maximum treatment duration of 60 months and follow-up up to 60 months after randomisation.

After signing the consent form, patients will enter the pre-inclusion period (before the start of treatment), during which the investigator will carried out all the tests required to assess their eligibility, including demographic data collection, tumour evaluation, and clinical and biological assessments.

Patients will receive doralutamide until disease progression or unacceptable toxicity for a maximum of 5 years after the start of treatment.

To receive treatment, the patient will need to go to hospital, where, at each visit, the medical team will conduct medical examinations before administering the treatment to assess the patient's general state of health and tolerance to the treatment.

03

Conditions studied

  • Prostatic Cancer, Castration-Resistant

Keywords

  • Phase 3
  • International
  • Multicentric
  • Randomised
  • Stereotactic body radiation therapy (SBRT)
  • PET-PSMA
  • mCRPC
  • nmCRPC
  • CRPC
  • oligometastases
  • functional imaging
  • darolutamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must have signed a written prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent.
  2. Patients aged ≥18 years.
  3. Patient with confirmed of adenocarcinoma prostate cancer without small cell or pure endocrine features.
  4. Patient with a history of local treatment with curative intent for localised prostate cancer, including surgery or radiotherapy.
  5. Patients with castration resistant prostate cancer, defined as either:

    • An increasing PSA level, confirmed in 3 consecutive assessments performed at least 1 week apart. This despite androgen deprivation therapy and castrate levels of testosterone.
    • Tumour progression of soft tissue according to the response criteria in solid tumours () version (v)1.1.
    • Tumour progression on bone scan, according to PCWG3 criteria.

    N.B. The two latter conditions only apply to the M1CRPC population.

  6. Detection of 1 to 5 sites (pelvic lymph nodes included) on new generation PET using either choline, fluciclovine, or PSMA as tracer.
  7. All metastatic sites must be amenable to stereotactic radiation therapy.
  8. Patient with normal haematological function: (ANC) >1.0 x 10⁹/L, count ≥100 x 10⁹/L, and ≥9.0 g/dL.
  9. Patient with normal liver function with total ≤1.5 (ULN) (unless documented Gilbert's syndrome), (ASAT) and alanine aminotransferase (ALAT) ≤2.5 ULN (≤5 ULN in the presence of liver metastases).
  10. Adequate liver function with bilirubin \<3 mg/dL and albumin >2.5 g/dL.
  11. Systolic blood pressure \<160 mmHg and diastolic blood pressure \<100 mmHg, as documented at baseline. Patients with hypertension are eligible if their hypertension is controlled and they meet all other eligibility criteria.
  12. Adequate kidney function with a >30 mL/min (Cockcroft-Gault).
  13. Patient with (ECOG) performance status (PS) ≤1.
  14. Patient is willing to use during and for at least 1 week after discontinuing darolutamide.
  15. Patient affiliated to the social security system (or equivalent according to local regulations for participation in clinical trials).
  16. Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Patient previously treated for prostate cancer with a novel hormonal agent (NHA), a CYP17 inhibitor, ketoconazole, chemotherapy, or immunotherapy.
  2. A history of cancer, other than the prostate cancer under study, within the 3 years prior to study inclusion, excluding cured localised cancer such as non-melanomatous skin cancer and non-muscle invasive bladder cancer.
  3. Presence of an uncontrolled disease or affection that according to the investigator will hinder compliance with the trial procedures or requires hospitalisation.
  4. Known to have active viral hepatitis, active (HIV) A at screening.
  5. Patients with known allergy or severe to the study treatment or any of its .
  6. Inability to swallow oral medications.
  7. Gastrointestinal disorder or procedure that can be expected to interfere significantly with the absorption of study treatment.
  8. Any of the following within 6 months before randomisation: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure (NYHA) Class III or IV.
  9. Patients participating in another therapeutic trial within the 30 days prior to randomisation.
  10. Patients unable to comply with trial obligations for geographic, social, or physical reasons, or who are unable to understand the purpose and procedures of the trial.
  11. Person deprived of their liberty or under protective custody or guardianship.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
336 participants (estimated)

Study arms

  • Active comparator
    ADT + darolutamide

    Up to 5 years of treatment

    Drug: Darolutamide 300 mg · Drug: Androgen deprivation therapy

  • Experimental
    ADT + darolutamide + SBRT

    Up to 5 years of treatment

    Drug: Darolutamide 300 mg · Radiation: Stereotactic body radiation therapy · Drug: Androgen deprivation therapy

Interventions

  • DrugDarolutamideStudies of DarolutamideDarolutamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2 tablets of 300 mg twice daily (=1200 mg/day) up to 5 years from randomisation

    Also known as: Nubeqa

  • RadiationStereotactic body radiation therapy

    Over one week,30 Gy in 3 fractions of 10 Gy

    Also known as: SBRT

  • DrugAndrogen deprivation therapy

    Continuous ADT during the study course. The choice of ADT is left to the discretion of the investigator.

    Also known as: ADT

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-free survival (rPFS)

    The radiographic Progression-free survival is defined as the time interval between the randomisation and radiographic disease progression with conventional imaging (CT-scan or bone-scan), or death due to any cause, whichever occurs first.

    Time frame: From randomization to disease progression or death, up to 5 years.

Secondary outcomes

  1. Time to treatment failure (TTF)

    The time to treatment failure is defined as the time interval between randomisation and the discontinuation of darolutamide, irrespective of the reason for discontinuation.

    Time frame: From randomization to discontinuation of darolutamide, up to 5 years

  2. Overall survival (OS)

    The overall survival is the length of time from randomization that patients enrolled in the study are still alive.

    Time frame: From randomization to death from any cause, up to 5 years.

  3. Prostate cancer-specific survival

    The prostate cancer-specific survival is defined as the time interval between randomisation and the date of death due to prostate cancer.

    Time frame: From randomization to death due to prostate cancer, up to 5 years.

  4. Time to PSA progression

    The time to PSA progression is defined as the time interval between the date of randomisation and the date of PSA progression. PSA progression is defined, in accordance with the PCWG3 guidelines which retained the PCWG2 definition (2007 guidelines).

    Time frame: From randomization to PSA progression, up to 5 years.

  5. Biochemical response rate

    The biochemical response rate is defined as the proportion of patients with a decrease in PSA levels of ≥50% from baseline levels.

    Time frame: Throughout study completion, up to 5 years.

  6. Time to next symptomatic skeletal event (SSE)

    The time to next symptomatic skeletal event is defined as the time interval from randomisation until the first occurrence of a symptomatic fracture, bone radiation (for pain or neurological complication), bone surgery (for pain or neurological complication), or spinal cord compression.

    Time frame: Time from randomization to the first symptomatic skeletal event, up to 5 years.

  7. Time to pain progression

    The time to pain progression is defined as the time interval from randomisation until the first occurrence of any of the following: * Increase of ≥2 points, from baseline, in question 3 of the Brief Pain Inventory-Short Form (BPI-SF) questionnaire (item related to the worst pain in the last 24 hours). * Initiation of opioid treatment for cancer pain. * Increase in the use of opioid treatment of ≥30% in terms of frequency of use or cumulative dose.

    Time frame: Time from randomization to the first occurence of pain progression, up to 5 years.

  8. Safety/tolerance

    The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.

    Time frame: Throughout study completion, up to 5 years.

  9. Functional Assessment of CAncer Therapy - Prostate (FACT-P)

    The FACT-P is a self-assessment questionnaire to estimate the health-related quality of life in men with prostate cancer. This questionnaire, composed of 39 items consists of four subscales: Physical Well-Being (7 items), Social/Family Well-Being (7 items), Emotional Well-Being (6 items), Functional Well-Being (7 items), and prostate cancer subscale (12 items). Subscales are rated on 5-point Likert-type scale (from 0 = "Not at all" to 4 = "Very much"). For all subscales, a higher score represents better quality of life.

    Time frame: At baseline, 1 month, every 4 months during treatment period, and at the end of treatment (up to 5 years).

  10. Brief Pain Inventory - Short Form (BP-SFI) questionnaire

    The Brief Pain Inventory (BPI) questionnaire rapidly assesses the severity of pain and its impact on functioning. This self-report questionnaire includes: * A body schema * The maximum pain, lowest pain, usual pain within the last 15 days (Numeric rating scales (NRS) 0 to 10) * Description of current analgesic treatment, * An assessment of relief by a percentage scale (0-100%), Assessment of the impact of pain on: mood, relationships with others, walking, sleep, work, happiness the joy - of living, recreation, activities in general (digital scales, rating from 0 \[normal\] to 10 \[no activity\]).

    Time frame: At baseline, 1 month, every 4 months during treatment period, and at the end of treatment (up to 5 years).

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Oct 2029, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2024
First posted
Feb 26, 2024
StartActual
Oct 7, 2024
Primary completionEst.
Oct 15, 2029
CompletionEst.
Oct 7, 2032
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06276465
Lead sponsor
UNICANCER
Collaborators
Bayer
Responsible party
Sponsor
First posted
Feb 26, 2024
Start date
Oct 7, 2024
Primary completion
Oct 15, 2029 (estimated)
Completion
Oct 7, 2032 (estimated)
Last update
Dec 20, 2024

Study contacts

Catherine LEGER
Contact
c-leger@unicancer.fr
0033 7 79 83 23 98
Meryem BRIHOUM
Contact
m-brihoum@unicancer.fr
0033 1 80 50 12 95
Ronan FLIPPOT, MD
principal investigator · Gustave Roussy (Villejuif, France)
David PASQUIER, MD
principal investigator · Centre Oscar Lambret, Lille University (Lille, France)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion